A groundbreaking study challenges conventional wisdom, revealing that hydroxyurea, a sickle cell medication, may not be as harmful during pregnancy as once believed. But is it time to rewrite the guidelines?
No Harmful Effects Found: The study, the first of its prospective nature, found no specific adverse effects on newborns when mothers took hydroxyurea during or shortly before pregnancy. This is a significant discovery, as the drug is often discontinued before pregnancy due to unknown risks.
Reassurance for Unplanned Pregnancies: The findings offer a sigh of relief for women with sickle cell disease who experience unplanned pregnancies while on hydroxyurea. Blood transfusions, an alternative treatment, are not always accessible or safe, making hydroxyurea a crucial option.
And here's where it gets controversial: Dr. Anoosha Habibi, the lead author, suggests a pragmatic approach, stating, "We have to decide case by case and evaluate the risk from transfusion and stopping hydroxyurea." This implies that continuing the medication during pregnancy might be a viable option in certain circumstances, despite the lack of extensive research.
Hydroxyurea is an oral drug designed to prevent sickle cell complications by maintaining healthy blood cell shapes. However, its use in pregnant women has been a mystery, leading to the standard advice of discontinuation three to six months before conception.
Dr. Habibi highlights the dilemma: "Many women are left untreated for months, risking severe complications." This is especially concerning in regions with limited access to safe blood transfusions, where stopping hydroxyurea could potentially harm both mother and fetus.
The study analyzed data from 178 pregnancies in women taking hydroxyurea, with most pregnancies appearing unplanned. The results showed a 75% live birth rate, no maternal deaths, and no newborn malformations linked to the drug.
Controversial Interpretation: Researchers conclude that continuing hydroxyurea during pregnancy might be a reasonable decision when transfusions are not feasible and the mother is at high risk of sickle cell complications. But is this interpretation too bold? More research is needed, especially to assess long-term effects on children exposed in the womb.
This study, funded by AddMedica and requested by the European Medicines Agency, is set to be presented by Dr. Habibi on December 7, 2025, leaving the medical community with a thought-provoking question: Should we reconsider our approach to hydroxyurea in pregnancy? Share your thoughts below!
